11. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. (1st November 2014) Authors: Rubel, D.M.; Spelman, L.; Murrell, D.F.; See, J.‐A.; Hewitt, D.; Foley, P.; Bosc, C.; Kerob, D.; Kerrouche, N.; Wulf, H.C.; Shumack, S. Journal: British journal of dermatology Issue: Volume 171:Number 5(2014:Nov.) Page Start: 1164 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Efficacy and safety of continuous every‐2‐week dosing of ixekizumab over 52 weeks in patients with moderate‐to‐severe plaque psoriasis in a randomized phase III trial (IXORA‐P). (15th May 2018) Authors: Langley, R.G.; Papp, K.; Gooderham, M.; Zhang, L.; Mallinckrodt, C.; Agada, N.; Blauvelt, A.; Foley, P.; Polzer, P. Journal: British journal of dermatology Issue: Volume 178:Number 6(2018) Page Start: 1315 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Efficacy and safety of continuous every‐2‐week dosing of ixekizumab over 52 weeks in patients with moderate‐to‐severe plaque psoriasis in a randomized phase III trial (IXORA‐P). (1st June 2018) Authors: Langley, R.G.; Papp, K.; Gooderham, M.; Zhang, L.; Mallinckrodt, C.; Agada, N.; Blauvelt, A.; Foley, P.; Polzer, P. Journal: British journal of dermatology Issue: Volume 178:Number 6(2018) Page Start: 1315 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. (14th December 2017) Authors: Gordon, K.B.; Blauvelt, A.; Foley, P.; Song, M.; Wasfi, Y.; Randazzo, B.; Shen, Y.K.; You, Y.; Griffiths, C.E.M. Journal: British journal of dermatology Issue: Volume 178:Number 1(2018) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. (1st January 2018) Authors: Gordon, K.B.; Blauvelt, A.; Foley, P.; Song, M.; Wasfi, Y.; Randazzo, B.; Shen, Y.K.; You, Y.; Griffiths, C.E.M. Journal: British journal of dermatology Issue: Volume 178:Number 1(2018) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies. (3rd July 2020) Authors: Strober, B.; Menter, A.; Leonardi, C.; Gordon, K.; Lambert, J.; Puig, L.; Photowala, H.; Longcore, M.; Zhan, T.; Foley, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 12(2020) Page Start: 2830 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Evidence‐ and consensus‐based (S3) Guidelines for the Treatment of Actinic Keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum – Short version. (14th September 2015) Authors: Werner, R.N.; Stockfleth, E.; Connolly, S.M.; Correia, O.; Erdmann, R.; Foley, P.; Gupta, A.K.; Jacobs, A.; Kerl, H.; Lim, H.W.; Martin, G.; Paquet, M.; Pariser, D.M.; Rosumeck, S.; Röwert‐Huber, H.‐J.; Sahota, A.; Sangueza, O.P.; Shumack, S.; Sporbeck, B.; Swanson, N.A. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 11(2015:Nov.) Page Start: 2069 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). (1st August 2021) Authors: Thaci, D.; Piaserico, S.; Warren, R.B.; Gupta, A.K.; Cantrell, W.; Draelos, Z.; Foley, P.; Igarashi, A.; Langley, R.G.; Asahina, A.; Young, M.; Falqués, M.; Pau‐Charles, I.; Mendelsohn, A.M.; Rozzo, S.J.; Reich, K. Journal: British journal of dermatology Issue: Volume 185:Number 2(2021) Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). (4th May 2021) Authors: Thaci, D.; Piaserico, S.; Warren, R.B.; Gupta, A.K.; Cantrell, W.; Draelos, Z.; Foley, P.; Igarashi, A.; Langley, R.G.; Asahina, A.; Young, M.; Falqués, M.; Pau‐Charles, I.; Mendelsohn, A.M.; Rozzo, S.J.; Reich, K. Journal: British journal of dermatology Issue: Volume 185:Number 2(2021) Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. (1st December 2021) Authors: Reich, K.; Gordon, K. B.; Strober, B. E.; Armstrong, A. W.; Miller, M.; Shen, Y. K.; You, Y.; Han, C.; Yang, Y. W.; Foley, P.; Griffiths, C. E. M. Journal: British journal of dermatology Issue: Volume 185:Number 6(2021) Page Start: 1146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗